EL7.AI
StocksMediumUpdated×2•Originally published 23 March 2026•Updated 24 March 2026•
1 min read

Lexicon and Novo Nordisk Launch Phase 1 Trial for Oral Obesity Drug LX9851

Key Facts

1Lexicon Pharmaceuticals and Novo Nordisk announced the initiation of a Phase 1 study for the drug candidate LX9851.
2LX9851 is a first-in-class, oral non-incretin candidate for the treatment of obesity and associated metabolic disorders.

Lexicon Pharmaceuticals and Novo Nordisk have officially initiated a Phase 1 clinical trial for their novel drug candidate, LX9851. Following the announcement, Lexicon Pharmaceuticals (LXRX) shares saw a positive price increase as investors reacted to the clinical milestone. This first-in-class oral treatment is designed to target obesity through a non-incretin mechanism, offering a unique approach to metabolic disorders. The partnership represents a strategic effort to diversify weight-loss treatments beyond the current dominance of GLP-1 receptor agonists. Analysts view this collaboration as a significant catalyst for Lexicon, leveraging Novo Nordisk's extensive global expertise in the metabolic space. The trial will primarily evaluate the safety and tolerability of the drug in human subjects for the first time.